Pfizer investors advised to reject executive pay proposal, says ISS

Investing.com -- Institutional Shareholder Services (ISS) has advised investors in Pfizer (NYSE: PFE ) to reject a proposal concerning executive compensation.

The suggestion comes in response to alterations in the long-term awards for CEO Albert Bourla and other top-ranking executives.

The proxy adviser revealed on Wednesday that these changes have resulted in an approximate increase of $1 million in additional value for the CEO.

The firm expressed concerns that these modifications significantly undermine the at-risk nature of the awards and the company’s pay-for-performance philosophy.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.